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IgE Basement Membrane Zone Antibodies Induce
Eosinophil Infiltration and Histological Blisters in
Engrafted Human Skin on SCID Mice
John J. Zone1, Ted Taylor1, Christopher Hull1, Linda Schmidt1,2 and Laurence Meyer1,2
Bullous pemphigoid (BP) is characterized by the deposition of IgG in the basement membrane zone, infiltration
of eosinophils, and blister formation. The purpose of this study was to evaluate a potential role of IgE basement
membrane antibodies in the histological findings of BP. LABD97 is a component of the shed ectodomain of
bullous pemphigoid antigen 2. We have developed an IgE hybridoma to LABD97 antigen. This hybridoma was
injected subcutaneously in SCID mice with engrafted human skin. A subcutaneous hybridoma secreting IgE
antibodies developed. An IgE mouse hybridoma to trinitrophenyl was used as a control. Human grafts and
mouse skin were examined grossly over 21 days, histologically, and immunopathologically at day 21 after
injection of the hybridoma. A visible subcutaneous tumor developed in 10–14 days. Erythema and intense
scratching developed 2–3 days before the tumor in test mice, but not in controls. At day 21, 16/16 test mice
developed intense eosinophil infiltration and degranulation of the human mast cells within the grafts and 13/16
developed histological, but not clinically visible, basement membrane blisters. Human skin grafts of control
mice and normal mouse skin on the test mice and control mice did not develop any histological abnormalities.
IgE antibodies to LABD97 recapitulate the histological inflammatory process seen in BP.
Journal of Investigative Dermatology (2007) 127, 1167–1174. doi:10.1038/sj.jid.5700681; published online 18 January 2007
INTRODUCTION
Bullous pemphigoid (BP) is an autoimmune inflammatory
mucocutaneous disease characterized clinically by urticarial
plaques, vesicles, and bullae on an erythematous base.
Histologically there is a basement membrane zone (BMZ)
blister located in the lamina lucida and infiltration of the
superficial dermis with eosinophils. IgG and complement
deposition is present at the BMZ, and IgG class circulating
BMZ antibodies are present (Borradori and Bernard, 2003).
The IgG antibodies react to the BMZ antigens BPAg1 (BP230,
a 230-kDa hemidesmosomal plaque protein) (Tanaka et al.,
1991), bullous pemphigoid antigen 2 (BPAg2) (BP180, type
XVII collagen, a 180-kDa hemidesmosomal transmembrane
protein) (Diaz et al., 1990; Giudice et al., 1992), and a
portion of the shed ectodomain of BPAg2 termed LABD97
(Meyer et al., 1991, 1990).
Although these IgG BMZ antibodies are widely believed to
be responsible for the inflammatory mucocutaneous process,
passive transfer of BP serum to mice failed to reproduce these
findings (Anhalt and Diaz, 1987). After noting that the
putative pathogenic epitopes (NC16A) of human BPAg2 were
not present in mouse skin, Liu et al. developed an IgG rabbit
antibody directed against the NC16a domain of the mouse
BPAg2. Passive transfer to neonatal mice produced neutro-
phil infiltration and a lamina lucida blister, but no eosinophil
infiltration was noted. This model does however replicate
some of the features of BP, including a grossly visible BMZ
blister and deposition of IgG and complement at the BMZ
(Liu et al., 1993).
LABD97 is a 97-kDa proteolytic fragment of BPAg2,
which was described on the basis of its reactivity with IgA
BMZ antibodies from both adult and childhood linear IgA
bullous dermatosis (LABD) of the lamina lucida type (Zone
et al., 1990, 1996, 1998). IgG antibodies to LABD97 which
do not react with intact BPAg2 are also present in the serum
of some BP patients (Meyer et al., 1990). The LABD97
epitope of BPAg2 is present in human skin, but not in mouse
skin, and this fragment of BPAg2 can be readily extracted
from normal human dermis (Zone et al., 1990). We have
previously developed IgG and IgA class mouse mAbs to
human LABD97 and passively transferred these antibodies to
athymic mice bearing human skin grafts (Zone et al., 2004).
Intense BMZ deposition of antibodies resulted, but there was
minimal inflammation with occasional neutrophils and
eosinophils and rare BMZ blisters.
There is some evidence that IgE antibodies may play a role
in BP. Increased IgE levels have been identified in 50–70% of
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patients with untreated BP (Arbesman et al., 1974; Delaporte
et al., 1996; Christophoridis et al., 2000; Bowszyc-Dmo-
chowska and Dmochowski, 2002; Dimson et al., 2003).
Fairley et al. (2005) recently reported that 8/10 untreated BP
patients had IgE antibodies that reacted with intact BPAg2.
Four of eight reacted with the NC16A region of BPAg2
whereas four reacted with sites downstream from NC16A.
CD23, a low-affinity receptor for IgE expressed on B
lymphocytes, was found to be higher in BP patients
compared to normals and tended to be higher in patients
with more severe disease, suggesting a potential role of IgE in
the pathogenesis of BP (Inaoki et al., 2004).
This study was designed to evaluate the role of IgE class
antibodies to LABD97 in a mouse model. We developed IgE
class mouse hybridomas to the human LABD97 antigen. The
hybridoma cells were injected subcutaneously into SCID
mice bearing human skin grafts that expressed the LABD97
antigen. In this report, we describe the clinical and
histological results that mimic human BP.
RESULTS
Human skin grafts develop erythema at days 8–11 after
subcutaneous injection of IgE hybridomas to LABD97
After injection of the hybridoma subcutaneously (day 0) in
the SCID mouse bearing a human skin graft, a visible
subcutaneous tumor developed in 11–14 days. At days 8–11,
before the development of a visible tumor, all 16 of the test
mice started to scratch intensely. The graft became visibly
erythematous and swollen (Figure 1). Control animals with
IgE hybridomas to trinitrophenyl (TNP) (n¼ 5) or phenylarso-
nate (n¼5) developed subcutaneous tumors but did not
scratch and did not develop erythema of the grafted skin.
Control animals with IgA hybridomas to LABD97 (n¼4) and
IgG hybridomas to LABD97 (n¼ 5) developed subcutaneous
tumors but did not scratch and did not develop erythema of
the grafted skin. Erythema of the mouse skin was not noted in
either the test animals or the controls.
Histological, but not clinical, BMZ blisters with eosinophil
infiltration develop in human skin but not in mouse skin
Biopsy of the human skin at day 0 revealed a scant superficial
perivascular infiltrate of lymphohistiocytic cells but no
evidence of neutrophil or eosinophil infiltration. There was
also no evidence of interface inflammation at the BMZ and
no evidence of antibody or complement deposition. Biopsy of
the human skin from the test animals at days 8–11 revealed
infiltration of the papillary dermis with eosinophils visible by
hematoxylin and eosin staining as well as staining for mouse
major basic protein (Figure 2). Eosinophilic spongiosis was
noted within the epidermis. The eosinophils were noted to be
intact and no evidence of degranulation of the mouse
eosinophils was noted. Occasional neutrophils were noted.
Early basement membrane blisters were noted in the samples
obtained at days 8–10. Harvest of the grafted skin and serial
sectioning at days 18–21 revealed basement membrane
separation in 13 of the 16 test animals (Figure 2). Evaluation
of the human skin grafts in the TNP and phenylarsonate
controls failed to reveal any evidence of eosinophil infiltra-
tion or BMZ separation at days 8–11 or at days 18–21.
Similarly, histological evaluation of the mouse skin in both
the test and control animals failed to reveal any evidence of
eosinophil infiltration or BMZ separation at days 8–11 or at
days 18–21. All final biopsies taken from the two control
groups revealed no blistering or other histopathological
changes different from the day 0 specimens. The results are
summarized in Table 1.
Intradermal injection of hybridoma supernatant into the human
skin graft
Intradermal injection of IgE LABD97 hybridoma fluid diluted
in phosphate-buffered saline revealed erythema and scratch-
ing within 15 minutes in 3/3 IgE LABD97 mice that received
100 ng/50ml. Biopsy at 24 hours revealed eosinophil infiltra-
tion without vesicle formation and IgE deposited at the BMZ.
IgE was noted to be bound to mast cells in the papillary
dermis. The three mice receiving IgE TNP revealed no
evidence of erythema or scratching at 15 minutes and no
eosinophil infiltration at 24 hours. Binding of IgE to mast cells
was noted in the dermis in all three animals receiving IgE
TNP. This indicates that IgE LABD97 but not IgE TNP is able
to produce inflammation in the absence of other systemic
factors that may occur in the subcutaneous hybridoma
model.
Immunomapping
Immunomapping of the basement membrane blister revealed
staining of the roof of the blister with BP serum and the base
of the blister with type IV collagen (Figure 3). This indicates
the lamina lucida as the location of the blister as is the case
in BP.
Figure 1. Mice receiving IgE anti-LABD97 hybridomas develop erythema in
human skin grafts. Photographs of SCID mice bearing human skin grafts at
day 21 after hybridoma cell injection. The control mouse (left) received a TNP
IgE hybridoma and demonstrated no erythema of the graft. The test mouse
(right) received an LABD97 IgE hybridoma and developed intense erythema.
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Control grafts
Goat anti-IgE injected intradermally into the grafts of the TNP
and phenylarsonate control mice at days 18–21 produced
edema and erythema visually apparent in 10–15 minutes. This
served to validate the presence and potential activity of IgE in
the control mice.
IgE is present at the basement membrane of test animals
Direct immunofluorescence evaluation of human skin grafts
and mouse skin at day 0 failed to reveal any evidence of
mouse or human C3, IgG, IgM, IgA, or IgE. This included an
absence of mouse IgE on dermal mast cells. Direct immuno-
fluorescence of erythematous skin at days 8–11 revealed
intense IgE in a linear pattern along the BMZ when areas
without vesiculation were present. In areas of vesiculation IgE
staining was either absent or minimally present in the roof of
the blister (Figure 4). Staining of both day 8–11 and day 18–21
skin grafts for mouse C3, IgG, IgM, and IgA was negative.
Mouse IgE serum levels in both the TNP and phenylarso-
nate controls ranged from 125 to 175mg/ml whereas IgE
levels in the test group ranged from 5 to 12mg/ml. The
disproportionate ratio seen in vivo between the test and
control groups mirrors that seen in the growth medium from
the hybridomas grown in vitro. SCID mice at baseline have
no detectable IgE in their serum. However, normal BALB/c
mice have levels up to 500 ng/ml (Seitzer et al., 2005). The
levels in our test mice are 10–24 times that of normal BALB/c
mice. These results are comparable to those published by
Dimson et al. (2003) for humans with BP. They noted that the
mean level of total IgE in untreated human BP patients was
3.3 times the upper limit of the normal with a maximum level
of 15 times normal.
The test animals demonstrated serum titers of IgE BMZ
antibodies adhering to the epidermal side of BMZ split skin at
titers of 1:10 at days 11–14 and negative indirect immuno-
fluorescence at day 21. Once again these numbers are
comparable to the data presented by Dimson et al. in
humans. They noted that 7/23 untreated BP patients had
circulating IgE BMZ antibody.
IgA and IgG LABD97 control animals failed to develop
inflammation
Biopsy of the IgA and IgG LABD97 control animals revealed
no significant infiltration of either neutrophils or eosinophils
and no blister formation at day 21. BMZ deposition of IgG
and IgA was noted in the IgG and IgA controls, respectively
(Table 1).
Human mast cells are present in the graft at day 0, bind IgE, and
degranulate during the inflammatory process
At day 0 the human graft stained positive for mast cells with a
rhodamine-avidin stain. Mast cells were distributed evenly
throughout the papillary and reticular dermis. Mast cells in
the graft also stained positive for human tryptase (Figure 5).
Mast cells in the mouse skin stained positive with rhodamine-
avidin and toluidine blue, but did not stain with the human
tryptase antibody (not shown). This indicates that the human
mast cells engrafted to the SCID mouse survive during the
graft maturation period. However, during the acute inflam-
matory process at days 8–11, only rare mast cells were visible
with the human tryptase stain in the papillary dermis whereas
human mast cells continue to be abundant in the reticular
dermis. At days 18–21 when mature histological blisters are
present, mast cells are again detectable in significant
numbers in the papillary dermis. This would seem to indicate
that during the acute inflammatory process the mast cells
have degranulated and subsequently regenerate their tryptase-
containing granules. Human mast cells at baseline fail to
show evidence of mouse IgE bound to their surface (not
shown). However, at days 18–21 IgE can be detected on the
a
b
c
Figure 2. Basement membrane blister and eosinophil infiltration at day 21 in
the dermis of a human skin graft of a mouse receiving IgE LABD97
hybridoma. (a) A basement membrane blister is seen at day 21.
Bar¼100 mm. (b) Eosinophils stained with hematoxylin and eosin are seen in
the dermis. (c) Eosinophils stained with antibody to major basic protein are
seen in the dermis. Bar¼25 mm.
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surface of the mast cells in the graft (Figure 5) and in the
normal mouse skin of both test animals and controls (not
shown).
The mean decrease in the numbers of mast cells in the test
animals comparing the day 8–10 samples with day 0 was
73% whereas in the controls there was an average gain of
100%. Others have also reported an increase in human
mast cells in grafted skin with time (Christofidou-Solomidou
et al., 1997).
DISCUSSION
We have developed a new animal model that reproduces the
clinical and histological findings of human BP. This includes
(a) an initial urticarial induration of the human skin
associated with scratching, (b) infiltration of the dermis with
an infiltrate that is predominantly eosinophils, (c) mast cell
degranulation, and (d) basement membrane vesiculation. It
should be realized that there is urticarial induration of the
skin that contains histological blisters, but no clinically
visible blisters. The histological blisters occur in the setting of
intense tissue eosinophilia, but we have not shown that the
eosinophil is essential in producing these blisters. These
characteristics of human BP are produced by the passive
transfer of IgE BMZ antibodies alone. In our previous work,
passive transfer of IgG and IgA antibodies directed against
the same LABD97 antigen failed to produce significant
inflammation. The dramatic and highly reproducible find-
ings of this study suggest that there may be a significant role
for IgE in the pathogenesis of human BP. The failure of others
to develop an animal model that involves eosinophil
infiltration may be related to the fact that passive transfer
models concentrated on the role of IgG alone (Liu
et al., 1993).
Table 1. Summary of results of mouse hybridoma experiments
Experimental animals Control animals
Hybridomas IgE LABD97 IgE LABD97 IgG LABD97 IgA LABD97 IgE TNP IgE PA
Tissue source Human graft Mouse skin Human graft Human graft Human graft Human graft
Erythema and scratching 16/16 0/16 0/5 0/4 0/5 0/5
BMZ blister 13/16 0/16 0/5 0/4 0/5 0/5
Eosinophils 16/16 0/16 0/5 0/4 0/5 0/5
BMZ IgE 16/16 0/16 0/5 0/4 0/5 0/5
BMZ IgG/C0 0/16 0/16 5/5 0/4 0/5 0/5
BMZ IgA 0/16 0/16 0/5 4/4 0/5 0/5
TNP, trinitrophenyl; PA, phenylarsonate.
a
b
Figure 3. Immunomapping of the basement membrane blister is in the
lamina lucida. A BMZ blister from the human graft of a test mouse is stained
with antibody to (a) BPAg2 and (b) type IV collagen. This localizes the blister
location to the lamina lucida. Bar¼50 mm.
Figure 4. Direct immunofluorescence of a basement membrane blister. The
section is stained with fluorescein conjugated anti-mouse epsilon chain.
IgE deposition is noted in the roof of the blister. Bar¼ 50 mm.
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This model utilizes IgE BMZ antibodies directed against
the LABD97 antigen and documents the pathogenicity of
antibodies to the LABD97 antigen. LABD97 is recognized as
a component of the shed ectodomain of BPAg2 (Zone et al.,
1998). As such it is shed into the dermis during the normal
proteolytic process and can be identified in the dermal
extract using standard extraction techniques (Zone et al.,
1990). The epitope recognized by our mouse hybridoma
antibody is not present in mouse skin (Zone et al., 2004). In
this model, antibodies to the antigen are pathogenic in
human skin where the antigen is present, but not pathogenic
in mouse skin where the antigen is absent. This is a key point
in our theory of pathogenesis in this model, as unbound
LABD97 antigen in the papillary dermis is available to
crosslink IgE bound to dermal mast cells. Our preliminary
work on this model has suggested to us that mast cell
degranulation is likely to be an essential component in the
evolution of inflammation. Although IgE bound to the mast
cells in the normal mouse skin, no inflammation took place.
We attribute this to the fact that LABD97 is a human protein
that is not present in mouse skin (Zone et al., 2004) and is
therefore not available in the papillary dermis for binding to
Fab sites and crosslinking IgE anti-LABD97 molecules that are
attached to mast cells by Fc binding. In order to prove this
hypothesis, it would be necessary to inject purified LABD97
into the mouse skin and evaluate for inflammation and mast
cell degranulation. We have not yet performed these
experiments, but are in the process of purifying larger
amounts of LABD97 for this purpose. In a similar manner,
the control TNP and phenylarsonate IgE hybridomas bind IgE
to the mast cells in both the human skin graft and the mouse
skin of the control animals. However, the TNP and
phenylarsonate antigens are not present in the dermis to
initiate mast cell degranulation. Moreover, these bound IgE
control molecules clearly possess the ability to degranulate
the dermal mast cells since the injection of anti-IgE into the
graft produces erythema and a wheal and flare response
within 10–15 minutes.
Binding of mouse IgE to human Fc epsilon R1 is an
essential component of this model. It has been well
established that there is in vitro cross-species binding of
mouse IgE with human basophils, mouse IgE binding with
human Fc epsilon R1, degranulation of human basophils by
mouse IgE, and subsequent release of enzymes. In vivo
mouse experiments with subsequent binding of mouse IgE to
human mast cells has also been successful (Ishizaka et al.,
1985; Hakimi et al., 1990; Haak-Frendscho et al., 1993; Mita
et al., 1995; Cho et al., 2000).
It is possible that other local factors produced by the
subcutaneous hybridomas contribute to the inflammatory
process that is seen in the test mice. If present, these factors
were not sufficient to produce inflammation in the mice with
IgG, IgA, TNP, or phenolarsonate hybridomas. In the future,
we plan to purify large amounts of IgE BMZ antibodies from
hybridoma cells and passively transfer this purified antibody
as we have done previously for IgA and IgG antibodies (Zone
et al., 2004). Preliminary attempts at this have been difficult
because of the relatively low amounts of IgE produced by the
IgE hybridomas compared to the IgA and IgG hybridomas.
We have not been able to produce significant histological
inflammation with IgG or IgA hybridomas. It seems likely that
if these antibodies are pathogenic, then additional pro-
inflammatory factors are required.
We have previously reported the results of passive transfer
of IgG and IgA class mouse monoclonal antibodies to
LABD97 to athymic mice bearing human skin grafts. This
was done by isolating antibody from mouse ascites fluid
rather than the current backpack mouse method and
subsequently administering the ascites fluid to the athymic
mice intraperitoneally (Zone et al., 2004). The passive
a
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Figure 5. The human grafts contain human mast cells that bind mouse IgE.
(a) The human graft at day 0 contains numerous mast cells that stain with
avidin. (b) The mast cells also stain with human tryptase indicating that they
are of human origin. Mast cells in mouse skin stain with avidin but not human
mast cell tryptase (not shown). (c) Mast cells in human skin graft from day 21
stain with anti-mouse epsilon chain. Cells also stain with avidin (not shown).
Bar¼50 mm.
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transfer of these IgG and IgA antibodies produced high
circulating titers of antibody and strong BMZ deposition of
antibody, but only a minimal inflammatory infiltrate of
eosinophils and neutrophils within the human skin grafts.
Microscopic early BMZ blisters without visible graft inflam-
mation were noted in 50% of the animals that received a
single IgG class LABD97 monoclonal antibody and 42% of
those that received IgA class antibody. The minimal
inflammation and vesiculation in these models suggests that
these early blisters might have been a result of interference
with the structural integrity of the BMZ conferred by BP180
rather than the inflammatory immunologic process believed
to be active in human BP. We noted no vesiculation or
inflammation in the human grafts from mice bearing IgG or
IgA hybridomas in the present experiments. LABD97 antigen
is known to be absent in generalized atrophic benign
epidermolysis bullosa, the hereditary condition in which
the BP180 gene is mutated (Shimizu et al., 1998). This
disorder does produce a minimally inflammatory blister
related to loss of the structural function of BP180.
Understanding the nature of the LABD97 antigen is central
to our theories of pathogenesis. We initially described the
LABD97 antigen as the predominant antigen to which serum
IgA anti-BMZ antibodies bound from patients with the lamina
lucida type of LABD and chronic bullous disease of child-
hood (Zone et al., 1990; Zone et al., 1996). We also
demonstrated that IgG from the serum of BP patients bound
LABD97 on immunoblot (Meyer et al., 1990, 1991).
Antibodies to the LABD97 antigen did not crossreact with
the transmembrane hemidesmosomal BP180 antigen (BPAg2)
on immunoblot. However, subsequently using amino-acid
sequencing of the immunoaffinity isolated LABD97 antigen,
we were able to determine that LABD97 is identical to the
extracellular component of BP180. LABD97 localizes on
electron microscopy between the NC16A and carboxy
terminal domains of BP180 (Ishiko et al., 1998). The lack of
cross-reactivity of LABD97 antibodies with BP180 on
immunoblot is still not explained. Attempts at binding our
LABD97 monoclonal antibodies to various fusion proteins of
BP180 have been unsuccessful (unpublished data). We have
hypothesized that the LABD97 antigen is a neoantigen that is
formed during the proteolytic cleavage of BP180.
Previous studies have strongly implicated a pathogenic
role of anti-BPAg2 IgG and neutrophils in BP blister formation
and degradation of BPAg2. Verraes et al. (2001) noted the
presence of neutrophil elastase in skin biopsies of BP patients
and recovered active enzyme from blister fluid. They
demonstrated that recombinant BPAg2 proteolysis occurred
with both neutrophil elastase and metalloproteinase 9, but a
specific elastase inhibitor and not an inhibitor of metallopro-
teinase could only inhibit the pattern of BPAg2 proteolysis
induced by BP blister fluid. Sitaru et al. (2002) have shown
that human and rabbit antibodies to the NC16A portion of
BPAg2 induced neutrophil-dependent subepidermal splits in
cryo-sections of human skin. This in vitro model is dependent
on binding of antibody to the extracellular portion of BPAg2.
There is little question that neutrophils in combination with
BMZ antibodies will induce BMZ separation. Our in vivo
model is not dependent on IgG antibodies to BPAg2 and does
not produce neutrophil accumulation at the BMZ. Although
neutrophil accumulation at the BMZ is not a characteristic of
human BP, the presence of neutrophil elastase in human BP
lesions and the in vitro effect of neutrophils indicate that
neutrophils may have a role in our model. It is likely that some
neutrophil infiltration has occurred in our model, although we
have detected only rare neutrophils with routine staining.
There may well be neutrophil elastase present in the tissue
and blister fluid in our model. We plan subsequent experi-
ments to evaluate the role of neutrophils, including depletion
of neutrophils from the test animals. We have not shown that
eosinophils are required for the inflammatory response in this
model, only that they are present. Eosinophils may be
bystanders in the inflammatory response or they may be
essential. We plan experiments that deplete mouse eosino-
phils in this model in order to experimentally address this
issue. However, for the purpose of this initial report, it is
important to realize that our model produces two histological
hallmarks of human BP, eosinophil infiltration and a lamina
lucida blister. Any possible role of the eosinophil in producing
the lamina lucida blister remains to be determined.
Liu et al. (1993) developed a mouse model used to study
BP It utilizes the passive transfer of IgG fraction rabbit
antibody directed against the mouse NC16A domain of
BP180. A visible BMZ blister as well as IgG and complement
deposition at the BMZ develop within 12–24 hours. These are
classical findings in human BP. However, this system utilizes
rabbit antibody, which is known to avidly fix complement.
The lack of eosinophils in the infiltrate suggests that an
immunopathological process is being produced, which is
different from that of human BP. It may be that a classical
Arthus reaction has been produced to a tissue antigen by a
complement-fixing antibody.
The model we have developed offers advantages for the
study of BMZ autoimmune bullous disease. It allows the
evaluation of the pathogenic role of individual antibody
classes. The current work demonstrates the value of that
approach. We have found that multiple immunoglobulins are
frequently present in the skin of BP patients (Zone et al.,
1994). This model also has the potential to allow the study of
the effect of IgE in combination with other immunoglobulins.
MATERIALS AND METHODS
Animals
Male C.B-17/Icr-SCID mice 5–6 weeks of age were obtained from
Charles River (Wilmington, MA). Animals were housed for 2–4
weeks before grafting, allowing them to acclimate to the new
environment in our housing facility. All experimental animals used
in this study were under a protocol approved by the Institutional
Animal Care and Use Committee of the University of Utah.
Preliminary experiments indicated that the previously utilized
athymic mouse model resulted in the production of mouse
antibodies against the cutaneous BMZ on direct immunofluores-
cence in all areas of the biopsies studied in approximately 20% of
mice. Consequently, we have utilized SCID mice and grafted human
foreskin to the mice as previously described (Zone et al., 2004).
Immunopathological evaluation of the graft showed no evidence of a
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humoral immune response to the human skin graft. Neonatal
foreskins from elective circumcision were obtained and transplanted
onto the upper backs of the mice after being trimmed of excess fat.
Skin was sutured, dressed, and allowed to heal for 10–14 days before
the dressings were removed. Grafts were allowed to mature for 8–10
weeks and only those that showed no signs of inflammation or
rejection were used.
Hybridoma cell line generation
IgG and IgA hybridomas were produced as described previously
(Zone et al., 2004). Acridine orange ICR191 (Sigma, St Louis, MO)
stimulation of our previously described IgG1 anti-LABD97 hybrido-
ma led to the recovery of an IgE isotype switch variant (Paizi et al.,
1995; Zone et al., 2004). In brief, the IgG hybridoma was treated
with ICR191 in cell culture and a subsequent IgE isotype switch
variant was isolated by decreasing cell density plating. Positive
producers were identified by enzyme-linked immunosorbent assay
spot assay on plates seeded with goat anti-mouse IgE antibody
(Bethyl Laboratories, Montgomery, TX) (Spira et al., 1996). Immuno-
blot of the IgE hybridoma antibody demonstrated reactivity with the
LABD97 antigen (a fragment of BPAg2 ) but not intact BP180 (not
shown). This is identical to the pattern seen for the parent IgG1 anti-
LABD97 hybridoma. Indirect immunofluorescence on a human split
skin substrate was performed using the supernatant from the IgE
hybridoma. There was strong binding of mouse IgE BMZ antibody to
the epidermal side of the BMZ (results not shown). This was identical
to the pattern seen previously for the parent IgG1 antibody (Zone
et al., 2004). Indirect immunofluorescence was performed on mouse
and human skin with the hybridoma-derived IgE. This demonstrated
strong binding to human BMZ and no binding to mouse BMZ. This
implies that the epitope recognized by our hybridoma antibody is
present in human but not in mouse BMZ.
Hybridoma cell line growth medium consisted of RPMI-1640
containing 10% fetal calf serum, 2 mM glutamine, 100 U/ml
penicillin, 100mg/ml streptomycin, and fungicide. Two control
hybridomas, one producing phenylarsonate-specific mouse IgE
monoclonal antibody (SE1.3) and the other TNP-specific mouse
IgE monoclonal antibody (IGELB4), were purchased from American
Type Culture Collection (Manassas, VA).
Backpack tumor production
Backpack tumors were produced as described previously (Winner
et al., 1991; Haneberg et al., 1997). Briefly, for each mouse, 1–2 106
hybridoma cells were washed twice in phosphate-buffered saline,
suspended in 0.2 ml phosphate-buffered saline, and then injected
subcutaneously into the upper back of the grafted SCID mice. To
ensure a maximum number of cells in log phase, a medium change
was always performed 6 hours before injection. Tumors were visible
at the injection site after 11–14 days. Tumor size for all mice selected
in the study ranged from 2 to 3 cm in diameter when the experiment
was terminated on day 21. The subcutaneous backpack tumor was
located in a site as far as possible from the human skin graft. In no
animals were the backpack tumors closer than 3–4 cm to the graft.
Intradermal injection of hybridoma supernatant into the human
skin graft
To further evaluate that the IgE LABD97 antibody itself was
responsible for the inflammatory response, we prepared IgE from
ascites fluid of mice bearing intraperitoneal IgE LABD97 and IgE TNP
hybridomas. Preparations consisting of 100 ng of IgE in 50 ml of
phosphate-buffered saline were used. This concentration was found
to be optimal in preliminary experiments. These preparations were
injected intradermally into human skin grafts of SCID mice bearing
no subcutaneous hybridoma. The mice were observed for 1 hour for
erythema and biopsies were performed at 24 hours.
Animal and graft evaluation
Graft and mouse skin from the test and control groups was visually
examined during the course of the experiment (18–21 days) for
erythema. At days 18–21 on visual examination, the mice were noted
to be actively scratching themselves. They were not able to reach the
graft itself, but were scratching the areas on their body that they were
capable of reaching. Biopsies were taken at selected time points and
immediately frozen or embedded in paraffin. These time points
consisted of day 0 and days 8–11. The graft was removed in its entirety
when the animals were killed at days 18–21 (end of experiment). Five
biopsies taken at days 8–11 when visible erythema developed were
evaluated for mast cell degranulation. Intradermal injection of goat
anti-mouse IgE (5mg/50ml, Bethyl Labs) into the graft on the control
mice was performed on day 21 (Gronneberg and Strandberg, 1985).
At the conclusion the animals were killed, serum was collected, and
mouse skin and the human graft were excised. Cryosections were
prepared and stained by direct immunofluorescence for the presence
of mouse antibodies and mast cells. Fluorescein isothiocyanate
conjugated goat anti-mouse IgG (Vector, Burlingame, CA), goat
anti-mouse IgM and C3 (Cappel, Irvine, CA), goat anti-mouse IgA
(Sigma, St Louis, MO), rat monoclonal anti-mouse IgE (Becton
Dickinson, San Diego, CA), and rhodamine conjugated avidin
(Vector) for the detection of human and murine mast cells, and
mouse monoclonal anti-human mast cell tryptase (Promega, Madison,
WI) were stained by conventional staining procedures. Paraffin-
embedded sections were prepared and stained with hematoxylin and
eosin and toluidine blue. Mouse eosinophil major basic protein was
stained with antibody supplied by Dr Kristin Leiferman.
Measurement of mouse IgE antibodies
IgE levels in mouse serum were determined by a mouse IgE
quantitative ELISA (Bethyl Laboratories, Montgomery, TX).
Immunomapping of blisters
Several graft biopsies from the test mouse group showing blisters at
the BMZ were stained by indirect immunofluorescence to determine
the location of the separation. Cryosections 6 mm thick were stained
with a mAb specific for human collagen IV (BD Biosciences, San
Diego, CA) and human serum reactive with BPAg2 antigen (Meyer
et al., 1990).
Quantification of mast cell degranulation
The extent of mast cell degranulation was determined by dividing
the difference of the average number of mast cells seen at the time of
visible erythema (8–10 days) by the average seen at 0 hour. Five
dermal papillary fields (original magnification  400) were con-
sidered in each group. This number is expressed as a percentage.
Mast cells were identified by fluorescent microscopy with rhoda-
mine-labeled avidin. Mouse skin as well as human graft was
examined from both the test animals and controls.
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